Therapy News and Research

RSS

Combining PARP inhibitors with existing cancer drugs promising

Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports.

23 Feb 2010

Multidisciplinary Head and Neck Cancer Symposium in Phoenix

The Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM, will host two news briefings on top head and neck cancer research from its meeting February 25-27, 2010, in Phoenix.

23 Feb 2010

Committee calls for strategies to curb hypertension

Public health officials and health care providers need to step up their efforts to reduce Americans' increasing rates of high blood pressure and better treat those with the condition, which triggers more than one-third of heart attacks and almost half of heart failures in the United States each year, says a new report from the Institute of Medicine.

23 Feb 2010

News outlets examine use of ART, microbicide development presented at conference

News outlets continue to report on the science discussed at the Conference on Retroviruses and Opportunistic Infections (CROI), which ended Friday in San Francisco.

23 Feb 2010

Pulmonx to raise new funding for global launch of Zephyr EBV and Chartis Pulmonary Assessment System

Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr® Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System. Both products are CE marked and cleared for sale in Europe and other major international markets.

23 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

CINJ researchers test malaria drug for colorectal cancer treatment

While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.

23 Feb 2010

AAAS meeting examines test-and-treat model's potential for fighting HIV spread, TB co-infection

Researchers speaking at the American Association for the Advancement of Science (AAAS) meeting on Saturday, discussed how a strategy to promote universal voluntary HIV tests and early antiretroviral treatment for patients living in high-risk areas might "derail the spread of [HIV/]AIDS, a battle where a successful vaccine remains elusive," the Associated Press/Washington Post reports

23 Feb 2010

Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced today that the companies have selected the combination treatment of pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, for advancement toward Phase 3 development. The decision to advance the program followed encouraging results from a 52-week blinded, placebo-controlled Phase 2 extension study. The pramlintide/metreleptin combination met the key target criteria of sustained and robust weight loss.

23 Feb 2010

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

A new guideline from the American Academy of Neurology recommends that the drug quinine, although effective, should be avoided for treatment of routine muscle cramps due to uncommon but serious side effects.

23 Feb 2010

FDA grants Fast Track designation for Curemark's CM-AT autism treatment

Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced that its CM-AT autism treatment, now in Phase III clinical trials, has been designated as a Fast Track drug by the U.S. Food and Drug Administration (FDA).

22 Feb 2010

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is extremely pleased to announce that it has entered into a collaborative agreement with Hadassah Medical Center to conduct its ALS clinical trials at the Hadassah Ein Kerem Hospital.

22 Feb 2010

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help develop the therapy.

22 Feb 2010

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.

22 Feb 2010

ResMed launches S9 sleep apnoea therapy platform in Europe

ResMed, a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment, today introduced its new cutting-edge sleep apnoea therapy platform called the S9 Series in Europe. The S9 Series combines a sleek design with superior functionality and more comfort. Combined climate control and humidification delivers unsurpassed comfort to the patient by controlling both the temperature and humidity that the patient breathes.

From ResMed Corp 22 Feb 2010

Testosterone replacement therapy may benefit male cancer survivors with testosterone deficiency

A new study has found that many male cancer survivors who develop testosterone deficiency after receiving chemotherapy or radiation therapy have an impaired quality of life and reduced energy levels. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study suggests that young male cancer survivors with testosterone deficiency may benefit from testosterone replacement therapy.

22 Feb 2010

WCMC-Q students receive new round of UREP funds totaling $280,000

Twenty-eight WCMC-Q students have received grants totaling $280,000 in the latest, seventh, round of funding from the Undergraduate Research Experience Program (UREP) to conduct advanced research projects with faculty members.

22 Feb 2010

Scientists develop new mathematical model to understand CML better

Doctors can now understand better chronic myeloid leukaemia (CML), including how it responds to therapy, thanks to a new mathematical model for the disease, developed by scientists in Portugal, Belgium and the United States. The work, to be published in the June edition of the journal Haematologica, also reveals that current therapies - which are not believed to cure CML - with the right protocol can actually get rid of the disease, and provides guidelines on how to do that.

21 Feb 2010

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

Many people who undergo treatment for hepatitis C develop hemolytic anemia, a disorder that destroys red blood cells. In some cases, it is so severe they have to reduce their medication or stop therapy altogether. But now, scientists in Duke University's Institute for Genome Sciences & Policy have discovered two genetic alterations linked to a benign enzyme condition that keep some patients anemia-free.

21 Feb 2010

Bleeding after percutaneous biopsy rare

Even among patients who have taken aspirin in proximity to an image-guided percutaneous biopsy, risk of major bleeding associated with the procedure is low, according to a study in the March issue of the American Journal of Roentgenology (www.ajronline.org). Image-guided percutaneous biopsies are an important means of diagnosing disease in organs and other soft tissues. They involve the removal of cells or tissues for examination.

20 Feb 2010

Therapy News and Research

Combining PARP inhibitors with existing cancer drugs promising

Multidisciplinary Head and Neck Cancer Symposium in Phoenix

Committee calls for strategies to curb hypertension

News outlets examine use of ART, microbicide development presented at conference

Pulmonx to raise new funding for global launch of Zephyr EBV and Chartis Pulmonary Assessment System

Study shows CEL-2000 vaccine blocks RA progression in mice

CINJ researchers test malaria drug for colorectal cancer treatment

AAAS meeting examines test-and-treat model's potential for fighting HIV spread, TB co-infection

Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

FDA grants Fast Track designation for Curemark's CM-AT autism treatment

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

ResMed launches S9 sleep apnoea therapy platform in Europe

Testosterone replacement therapy may benefit male cancer survivors with testosterone deficiency

WCMC-Q students receive new round of UREP funds totaling $280,000

Scientists develop new mathematical model to understand CML better

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

Bleeding after percutaneous biopsy rare

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News